A Double-Blind, Parallel, Randomized Comparison of Two Doses of MitoQ [mitoquinone] and Placebo for the Treatment of Patients With Raised Liver Enzymes Due to Hepatitis C

Trial Profile

A Double-Blind, Parallel, Randomized Comparison of Two Doses of MitoQ [mitoquinone] and Placebo for the Treatment of Patients With Raised Liver Enzymes Due to Hepatitis C

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Jan 2010

At a glance

  • Drugs Mitoquinone (Primary)
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Sponsors Antipodean Pharmaceuticals
  • Most Recent Events

    • 24 Apr 2008 The primary endpoint and other results have been reported in an Antipodean Pharmaceuticals media release.
    • 14 Apr 2008 New trial record.
    • 10 Apr 2008 Results will be presented at the EASL annual meeting in April 2008.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top